- Tension: A treatment that works partly because of what you believe is happening quietly dismantles medicine’s assumption that expectation and effect can be cleanly separated.
- Noise: Breathless headlines about psilocybin’s results bury the trial’s most honest finding — that researchers couldn’t actually blind their participants to what they’d taken.
- Direct Message: When the experience itself appears to be the mechanism, science hasn’t found a flaw in the method — it’s stumbled onto something far more interesting about how healing actually works.
To learn more about the DM News editorial approach, explore The Direct Message methodology.
I should tell you where I’m coming from on this. I’m from Georgia — the country, not the state. Georgia, the former Soviet republic nestled between Europe and Asia, has some of the most aggressive drug laws in the post-Soviet world. Psilocybin is very much illegal there, as is a remarkable number of other things that much of the world has started treating as nuanced. In Georgia, you don’t just lack access to psilocybin-assisted therapy — you lack access to the conversation. The subject exists in a kind of sealed black box, somewhere between taboo and dangerous, and the box is firmly not encouraged to be opened.
All of which means I’ve been reading the recent wave of psychedelic research with the hunger of someone watching a party from outside a locked window. Not advocacy — I want to be clear about that. What I’m genuinely dying to understand is how it actually works. The mechanism. The neuroscience. Not the headline results, but the deeper question: what is actually happening inside a brain when a single dose produces improvements that last for months?
The latest addition to that pile arrived this month, and it’s worth sitting with carefully.
What the study actually did
The research, published in JAMA Network Open in May 2026 and led by Hampus Yngwe and Johan Lundberg at the Karolinska Institutet in Sweden, enrolled 35 participants with recurring depression. That framing matters: this was not a treatment-resistant population — not people for whom every conventional option had already failed. These were people with recurrent episodes, which is a more common profile and, in some ways, a more demanding test. If psilocybin only works after everything else has failed, it remains a last resort. If it works for ordinary recurring depression, the implications are considerably wider.
Participants were split into two groups. One received a single dose of psilocybin with psychological support. The other received vitamin B3 — niacin — chosen because it produces physical sensations similar to psilocybin: skin flushing, warmth, a slight altered feeling that mimics, without replicating, the real thing. Both groups received identical levels of psychological support. The active placebo rather than a sugar pill is a genuine methodological improvement — designed to make it harder for participants to correctly guess which group they were in.
Whether it succeeded is a question I’ll come back to.
What they found
By day eight — one week after a single dose — participants in the psilocybin group were showing noticeable improvements in mood. That alone is striking; most conventional antidepressants take weeks to produce any measurable effect, and the early weeks are often the worst, not the best.
At six weeks, the gap widened sharply. More than half of the psilocybin group no longer met the clinical criteria for depression. In the placebo group, that number was one person. The difference is not subtle.
The benefits held for just over three months on self-rated outcomes, then the gap between the groups narrowed — not because the psilocybin group crashed, but because the placebo group also started to improve. Depression, as most people who’ve lived with it know, tends to lift eventually on its own. The question is whether you can shorten the trough.
The blinding problem
Here is the part the researchers themselves flag, and that deserves more attention than it gets in the breathless coverage of psychedelic studies: almost everyone correctly guessed which group they were in.
Psilocybin produces an unmistakable altered state. Niacin does not. Whatever the physical mimicry of skin flushing, it evidently cannot fool someone who is also experiencing — or very much not experiencing — a significant shift in consciousness. When you know you’ve taken a potentially transformative compound, and especially when you’ve sought out a clinical trial to receive it, you arrive with expectations. Those expectations are not nothing.
The authors are direct about this: expectation likely amplifies benefit in the psilocybin group, while knowing you received the placebo may suppress improvement in the control group. This doesn’t invalidate the findings — but it means the therapeutic effect is probably some combination of direct pharmacological action and what you believe is happening to you. Disentangling those two things is, currently, effectively impossible.
How it actually works, as far as anyone knows
Psilocybin — specifically its active metabolite psilocin — acts primarily on serotonin receptors, and in particular on the 5-HT2A receptor, which is densely distributed in the cortex and plays a significant role in mood and cognition. But the serotonin story is probably not the whole story. Psilocybin also appears to promote neuroplasticity — the brain’s capacity to form new connections and reorganise existing ones. There is evidence of increased synaptogenesis: the literal growth of new synaptic connections in areas associated with mood regulation.
The working hypothesis is that depression is partly a disorder of rigid cognition. The same thoughts, the same loops, the same neural grooves — with diminishing capacity to find a way out. Psilocybin may temporarily loosen that rigidity, creating a window in which the brain is more plastic, more open to restructuring. The psychological support accompanying the dose may be doing significant work precisely during this window, when the brain is theoretically more receptive to new ways of framing experience.
Similar findings have started to appear with related compounds. A recent DMT study found rapid reductions in major depression from a single dose, suggesting the mechanism may be shared across a class of compounds that act on the same receptors — not unique to psilocybin specifically.
The bigger picture
What strikes me about this study is not that it proves anything definitively — 35 participants is a small sample, and the blinding problem is real. What strikes me is the consistency of the signal. Study after study finds that a single guided psychedelic experience produces antidepressant effects lasting weeks to months, in a population broader than just treatment-resistant cases, through a mechanism that is biologically plausible.
What the research cannot yet answer is how to scale this. The altered state isn’t incidental — it appears to be load-bearing. You can’t strip out the experience and keep the effect. Which means any real therapeutic application requires trained facilitators, appropriate settings, and genuine psychological preparation. None of that is cheap. None of it is simple. And in Georgia, none of it is even discussable.
I’m not sure what to do with that, except notice it. The box stays sealed. The question of whether what’s inside might actually help people is, for now, not one we’re permitted to ask out loud.
I’m asking it here anyway.
